Literature DB >> 20798438

Outcomes of revision total hip replacement for infection after grading according to a standard protocol.

S I S Oussedik1, M B Dodd, F S Haddad.   

Abstract

Periprosthetic infection following total hip replacement can be a catastrophic complication for the patient. The treatments available include single-stage exchange, and two-stage exchange. We present a series of 50 consecutive patients with a diagnosis of infected total hip replacement who were assessed according to a standardised protocol. Of these, 11 underwent single-stage revision arthroplasty with no recurrence of infection at a mean of 6.8 years follow-up (5.5 to 8.8). The remaining 39 underwent two-stage revision, with two recurrences of infection successfully treated by a second two-stage procedure. At five years, significant differences were found in the mean Harris Hip Scores (single-stage 87.8; two-stage 75.5; p = 0.0003) and in a visual analogue score for satisfaction (8.6; 6.9; p = 0.001) between the single- and two-stage groups. Single-stage exchange is successful in eradicating periprosthetic infection and results in excellent functional and satisfaction scores. Identification of patients suitable for the single-stage procedure allows individualisation of care and provides as many as possible with the correct strategy in successfully tackling their periprosthetic infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20798438     DOI: 10.1302/0301-620X.92B9.23663

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  36 in total

1.  The use of spacers (static and mobile) in infection knee arthroplasty.

Authors:  Luca Mazzucchelli; Federica Rosso; Antongiulio Marmotti; Davide Edoardo Bonasia; Matteo Bruzzone; Roberto Rossi
Journal:  Curr Rev Musculoskelet Med       Date:  2015-12

Review 2.  Single- or two-stage revision for infected total hip arthroplasty? A systematic review of the literature.

Authors:  Hugh A C Leonard; Alexander D Liddle; Orlaith Burke; David W Murray; Hemant Pandit
Journal:  Clin Orthop Relat Res       Date:  2013-09-21       Impact factor: 4.176

3.  What is the Long-term Economic Societal Effect of Periprosthetic Infections After THA? A Markov Analysis.

Authors:  Thomas J Parisi; Joseph F Konopka; Hany S Bedair
Journal:  Clin Orthop Relat Res       Date:  2017-04-07       Impact factor: 4.176

4.  CORR Insights®: Single-stage Acetabular Revision During Two-stage THA Revision for Infection is Effective in Selected Patients.

Authors:  Dror Lakstein
Journal:  Clin Orthop Relat Res       Date:  2017-04-25       Impact factor: 4.176

5.  CORR Insights®: What is the Long-term Economic Societal Effect of Periprosthetic Infections After THA? A Markov Analysis.

Authors:  Don C Beringer
Journal:  Clin Orthop Relat Res       Date:  2017-04-27       Impact factor: 4.176

6.  Should well-fixed uncemented femoral components be revised in infected hip arthroplasty? Report of five trial cases.

Authors:  Kiyokazu Fukui; Ayumi Kaneuji; Syusuke Ueda; Tadami Matsumoto
Journal:  J Orthop       Date:  2015-11-01

Review 7.  The Role of One-Stage Exchange for Prosthetic Joint Infection.

Authors:  Fiachra E Rowan; Matthew J Donaldson; Jurek R Pietrzak; Fares S Haddad
Journal:  Curr Rev Musculoskelet Med       Date:  2018-09

8.  Pre-operative scoring system to determine the surgical strategy for periprosthetic hip infection.

Authors:  Kenichi Oe; Hirokazu Iida; Narumi Ueda; Tomohisa Nakamura; Naofumi Okamoto; Yusuke Ueda
Journal:  Int Orthop       Date:  2014-08-17       Impact factor: 3.075

9.  Routine one-stage exchange for chronic infection after total hip replacement.

Authors:  Jean-Yves Jenny; Régis Lengert; Yann Diesinger; Jeannot Gaudias; Cyril Boeri; Jean-François Kempf
Journal:  Int Orthop       Date:  2014-07-31       Impact factor: 3.075

10.  Success after treatment of periprosthetic joint infection: a Delphi-based international multidisciplinary consensus.

Authors:  Claudio Diaz-Ledezma; Carlos A Higuera; Javad Parvizi
Journal:  Clin Orthop Relat Res       Date:  2013-02-26       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.